India has come a long way in the management of cardiovascular disease. With advances in diagnostics, interventional cardiology and cardiac surgery, patients with complex heart conditions have more options than ever before. However, access to newer su
If you stand at a chemist counter in Delhi for half an hour, you'll notice something. A good share of what people ask for is skin related: a cream for a rash that won't go
Roche’s next-generation drug divarasib cuts lung cancer death risk by 44%, offering longer survival and improved treatment tolerability.
CLDN18.2 testing is gaining attention as AstraZeneca's experimental stomach cancer drug shows survival benefits, potentially widening eligibility for targeted treatment among patients.
NAPCON 2026 highlights how artificial intelligence can support early detection of tuberculosis and lung cancer through advanced medical imaging.
AIIMS Nagpur secures Rs 30 crore for a Biosafety Level III laboratory, strengthening Maharashtra’s pathogen detection and infectious disease preparedness.
Novartis' Remibrutinib data highlight new findings on relapse reduction, disability progression and the potential role of oral therapies in multiple sclerosis.
This week’s key IPO results spotlight Roche’s India growth, Abbott’s nutrition spin-off, Bajaj Healthcare’s strong Q2, and Moderna-Merck’s cancer vaccine breakthrough.
Dr Reddy’s tackles an Ozempic supply disruption, Sun Pharma faces bond market pressure, and Merck-Moderna advance cancer vaccine research.
The AbbVie lutikizumab trial met its Phase 3 primary endpoint in hidradenitis suppurativa, while the company prepares to explore an obesity-focused combination strategy.
.jpg)
, CDSCO.jpg "Fostering a Quality Culture in the Pharmaceutical Industry")
